I'm not sure what your point is here. No one is denying who collobarated to produce the article. I'm making you aware that within the article, the 28,000 patients mentioned refers to all patients receiving a MM prescription in Australia, not just MXC's patients. An article can contain wider industry data while being focused on a particular company, which is the case here...
pot stock, page-9
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RGT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.00M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3300 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 313 | 1 |
View Market Depth
| Last trade - 16.16pm 12/07/2024 (20 minute delay) ? |
| RGT (ASX) Chart |
Day chart unavailable